PFE vs SLB: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
VS
SLB N.V. · Energy
$51.92
-20.2% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
SLB |
| Current Price |
$26.91 |
$51.92 |
| Fair Value Estimate |
$35.00 |
$41.43 |
| Upside to Fair Value |
+30.1%
|
-20.2%
|
| Market Cap |
$153.0B |
$77.9B |
| Forward P/E |
9.5x
|
18.6x
|
| EV / EBITDA |
13.8x
|
9.2x
|
| Price / Sales |
2.4x
|
2.2x
|
| Price / FCF |
16.8x
|
16.1x
|
| Revenue Growth YoY |
-1.6%
|
-1.6%
|
| Gross Margin |
70.3%
|
18.21%
|
| Operating Margin |
24.7%
|
15.28%
|
| Return on Equity |
9.0%
|
12.83%
|
| Dividend Yield |
6.4% |
2.21% |
| FCF Yield |
5.9%
|
6.21%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
SLB is the world's largest oilfield services company with $35.7B in FY2025 revenue, operating across four divisions: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems. The company completed the ChampionX acquisition in 2025 and is pursuing a digital transformation and AI-driven strategy. At $51.92, SLB trades at 2.18x P/S (in the fair range of the 5-year di…
Accumulation Zones
| Metric |
PFE |
SLB |
| Zone Low |
$25.00 |
$34.00 |
| Zone High |
$29.00 |
$39.00 |
| In Buy Zone? |
Yes
|
No
|